HIMS News

Hims & Hers Health stock has lost momentum this year. After peaking at $72.78 in 2025, it has slumped about 65% to the current $26.read more...

Key PointsHims & Hers Health is leveraging a high-growth, subscription-based digital platform to provide personalized treatments for weight loss and sexual health...

Hims & Hers Health gears up for Q3 earnings, with weight loss demand, international expansion and subscriber growth fueling revenues despite margin pressures.

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines Lilly and Hims & Hers expand access to FDA-approved Lilly medicinesPR NewswireINDIANAPOLIS, Nov. 6, 2026 Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platformINDIANAPOLIS...

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $24.06, indicating a -9.75% shift from the previous trading day.

New HHS Direction Creates Potential Opportunities For Peptide Manufacturers, Biotech Companies, And Healthcare Innovators    New York, NY –November 5, 2026 – The federal government’s October 30, 2026, decision could be a big deal for the peptide industry. HHS has signaled that it does not intend to pursue enforcement action against qualifying state-licensed pharmacies, federal […] The post Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across The $164 Billion Peptide Market appeared first on Financial News Media.

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced four new partners joining Hims & Hers Benefits: Grns, Medjet, Tonal, and Viome. The program launched in March with two partners and has grown to include 14, with benefits designed to support subscribers...

Privia Health (PRVA) delivered earnings and revenue surprises of +11.11% and +9.57%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ("Hims or the Company) (NYSE: HIMS) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that...